Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycem
June 07 2008 - 12:00PM
PR Newswire (US)
DURATION-1 Data Presented at the 68th Annual Scientific Sessions of
the American Diabetes Association SAN FRANCISCO, June 7
/PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(NASDAQ:AMLN), Eli Lilly and Company (NYSE:LLY), and Alkermes, Inc.
(NASDAQ:ALKS) announced results from a 30-week study that compared
the efficacy of exenatide once weekly, a long-acting release
formulation of exenatide, to BYETTA(R) (exenatide) injection. Type
2 diabetes patients treated with exenatide once weekly, an
investigational therapy, showed statistically significant
improvements in A1C (-1.9%+/-0.08 (LS mean+/-SE)) and fasting
plasma glucose (FPG -42+/-3 mg/dL) from baseline and compared with
BYETTA (-1.5%+/-0.08, A1C and -25+/-3 mg/dL, FPG). Patients in both
treatment groups also reported significant weight loss (average of
8 pounds) and 77 percent of patients treated with exenatide once
weekly achieved an A1C of 7 percent or less. These findings were
presented at the 68th Annual Scientific Sessions of the American
Diabetes Association (ADA) in San Francisco. BYETTA is indicated as
adjunctive therapy to improve glycemic control in patients with
type 2 diabetes mellitus who are taking metformin, a sulfonylurea,
a thiazolidinedione, a combination of metformin and a sulfonylurea,
or a combination of metformin and a thiazolidinedione but have not
achieved adequate glycemic control. "We know that a substantial
number of type 2 diabetes patients are overweight, and conventional
diabetes therapies, while controlling blood glucose, may have
little or no beneficial impact on body weight. Importantly, the
DURATION-1 results suggested the significant, beneficial impact of
continuous levels of exenatide once weekly on glycemic control, and
additionally, weight loss," said Daniel J. Drucker, M.D., Professor
in the Division of Endocrinology, Department of Medicine, of
Toronto, Director of the Banting and Best Diabetes Centre. Study
Design and Findings The Diabetes Therapy Utilization: Researching
Changes in A1C, Weight and Other Factors Through Intervention with
Exenatide ONce Weekly (DURATION-1) study was a 30-week, randomized,
open-label study of 295 patients with type 2 diabetes (baseline
values: A1C 8.3%+/-1.0, FPG 169+/-43 mg/dL, weight 225+/-44 lbs.,
BMI 35+/-5.0 kg/m2, diabetes duration 6.7+/-5.0 years; mean+/-SD)
who were treated with exenatide once weekly 2.0 mg or BYETTA twice
daily as outlined in the approved label subcutaneously. Patients in
both groups who completed the randomized portion of the study
continued in an open-ended portion of the study to receive
exenatide once weekly. Patients in both treatment arms showed
improvements in A1C from baseline. In addition, treatment with
exenatide once weekly resulted in statistically significant
reductions in A1C [A1C change from baseline: 1.9%+/-0.08] compared
to BYETTA [A1C change from baseline: 1.5%+/-0.08 (P=0.002)].
Seventy-seven percent of patients treated with exenatide once
weekly achieved an A1C of 7 percent or less versus 61 percent for
BYETTA (P=0.004). The ADA-recommended target for good glucose
control is an A1C of below 7 percent. For patients entering the
study with a baseline A1C of 9 percent or greater, at endpoint, 29
percent of patients treated with exenatide once weekly achieved A1C
levels of 6.5 percent or less versus 13 percent for BYETTA. Both
BYETTA and exenatide once weekly treatment groups showed
significant glycemic improvements irrespective of baseline A1C.
Treatment with exenatide once weekly also resulted in significant
lowering of FPG concentrations (reductions of -42+/-3 mg/dL,
exenatide once weekly; - 25+/-3 mg/dL, BYETTA, P
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024